• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Baxter Appoints William Ampofo to Its Board

    6/29/23 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care
    Get the next $BAX alert in real time by email

    Addition of Mr. Ampofo complements and expands current board expertise, reflects focus on continued board refreshment efforts

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed William A. Ampofo II, chair, Supply Chain Operations Council and vice president, Parts & Distribution Services and Supply Chain, Boeing Global Services, to its board of directors. Mr. Ampofo will serve on Baxter's Quality, Compliance & Technology Committee. His appointment is effective today and brings the total number of directors serving the company to 11.

    "William's deep operational expertise, track record as a supply chain leader, and distinguished career driving transformation at multinational companies will enrich and further differentiate our current board membership," said José (Joe) E. Almeida, chairman, president and chief executive officer. "We are excited to welcome William to Baxter's board and look forward to his many contributions."

    William Ampofo

    Mr. Ampofo has worked for the Boeing Company since 2016 and currently serves as the leader of the Parts & Distribution Services business and the Global Services Supply Chain function for Boeing Global Services. In this capacity, he leads all aspects of the supply chain function, including a division with operations in over 70 countries and more than 300 locations around the world. Prior to joining Boeing, Mr. Ampofo spent 22 years at United Technologies Corporation (UTC) working in roles of increasing responsibility related to finance, information technology, corporate strategy and operations. Mr. Ampofo earned a bachelor's degree in finance from Adelphi University and a Master of Business Administration from George Washington University. He is a member of The Executive Leadership Council and currently serves on the board of directors for the General Aviation Manufacturers Association and the Dallas Regional Chamber as well as the board of trustees for Cheshire Academy in Cheshire, Connecticut. In addition, he is a past advisory board member for Howard University's Center of Excellence in Supply Chain Management.

    About Baxter

    Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company's rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.

    Baxter is a registered trademark of Baxter International Inc.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230629292950/en/

    Get the next $BAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BAX

    DatePrice TargetRatingAnalyst
    10/31/2025Buy → Hold
    Argus
    8/4/2025$25.00Buy → Hold
    Stifel
    8/1/2025$25.00Buy → Neutral
    Goldman
    2/26/2025$42.00Buy
    Goldman
    2/24/2025Hold → Buy
    Argus
    2/20/2025$39.00Overweight
    Barclays
    7/15/2024$39.00 → $30.00Equal-Weight → Underweight
    Morgan Stanley
    5/30/2024$36.00Neutral
    Goldman
    More analyst ratings

    $BAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP,Group President,Pharma Sonig Alok covered exercise/tax liability with 3,191 shares, decreasing direct ownership by 2% to 128,219 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    9/4/25 6:02:32 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    President and CEO Hider Andrew P. was granted 368,050 shares (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    9/4/25 6:01:54 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    EVP and CFO Grade Joel T. was granted 102,712 shares, increasing direct ownership by 86% to 222,560 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    9/4/25 6:01:18 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    SEC Filings

    View All

    Baxter International Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    11/25/25 4:45:37 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form FWP filed by Baxter International Inc.

    FWP - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    11/19/25 5:17:33 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter International Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    11/19/25 4:21:24 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Baxter downgraded by Argus

    Argus downgraded Baxter from Buy to Hold

    10/31/25 8:47:22 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter downgraded by Stifel with a new price target

    Stifel downgraded Baxter from Buy to Hold and set a new price target of $25.00

    8/4/25 8:18:58 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter downgraded by Goldman with a new price target

    Goldman downgraded Baxter from Buy to Neutral and set a new price target of $25.00

    8/1/25 8:11:11 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    INVESTIGATION ALERT: Berger Montague PC Investigates Baxter International Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: BAX)

    PHILADELPHIA, Dec. 1, 2025 /PRNewswire/ -- Berger Montague advises shareholders of Baxter International Inc. ("Baxter" or the "Company") (NYSE:BAX) about an investigation into Baxter's Board of Directors for potential breaches of fiduciary duties to the Company and its shareholders in connection with Baxter's marketing and sale of its Novum Large Volume Pump ("Novum LVP").  Shareholders of Baxter may learn more about this investigation by contacting Berger Montague: Radha Raghavan at [email protected] or (332) 271-8908, or Andrew Abramowitz at aabramowitz@bergermont

    12/1/25 9:11:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    INVESTIGATION ALERT: Berger Montague PC Investigates Baxter International Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: BAX)

    PHILADELPHIA, Nov. 25, 2025 /PRNewswire/ -- Berger Montague advises shareholders of Baxter International Inc. ("Baxter" or the "Company") (NYSE:BAX) about an investigation into Baxter's Board of Directors for potential breaches of fiduciary duties to the Company and its shareholders in connection with Baxter's marketing and sale of its Novum Large Volume Pump ("Novum LVP").  Shareholders of Baxter may learn more about this investigation by contacting Berger Montague: Radha Raghavan at [email protected] or (332) 271-8908, or Andrew Abramowitz at aabramowitz@bergermon

    11/25/25 5:06:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Announces Increase in Maximum Tender Cap for 1.915% Senior Notes Due 2027

    Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced that it has increased the maximum purchase price for its $1.45 billion aggregate principal amount outstanding of 1.915% Senior Unsecured Notes due 2027 (the "2027 Notes") that it can repurchase under its previously announced cash tender offer for the 2027 Notes (the "2027 Notes Tender Offer") from $300 million to $600 million, on the terms and subject to the conditions set forth in the related Offer to Purchase dated Nov. 19, 2025 (the "Offer to Purchase"). The terms of the previously announced cash tender offer by Baxter for its 2.600% Senior Unsecured Notes due 2026 (the "2026 Notes Tender Offer" and, togethe

    11/19/25 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Leadership Updates

    Live Leadership Updates

    View All

    Baxter Appoints Andrew Hider Chief Executive Officer

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments. Brent Shafer, who has served as chair and interim CEO since February 2025, will then transition to independent chair of the Baxter Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250706840140/en/Andrew Hider Appointed Baxter's Next CEO Since 2017, Mr. Hider has served as

    7/7/25 8:35:00 AM ET
    $ATS
    $BAX
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    Amerant Bancorp Announces Appointment of Two New Board Members

    Amerant Bancorp Inc. (NYSE:AMTB) ("Amerant" or "the Company") and its subsidiary, Amerant Bank, N.A. (the "Bank"), today announced the appointment of two accomplished executives, Patricia "Patty" Morrison and Jack Kopnisky, to the Board of Directors of the Company and the Bank. Their addition reflects the Company's continued commitment to strategic growth and further strengthening of the Board of Directors and executive management. "We are delighted to welcome both Patty and Jack to our Board of Directors," said Jerry Plush, Chairman and CEO of Amerant and the Bank. "Patty's deep technology leadership and extensive board expertise, paired with Jack's enviable experience in leading high pe

    6/24/25 9:20:00 AM ET
    $AMTB
    $BAX
    $WBS
    Major Banks
    Finance
    Medical/Dental Instruments
    Health Care

    PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    3/11/25 7:05:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    $BAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Baxter International Inc.

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    11/13/24 1:08:27 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Baxter International Inc. (Amendment)

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    2/13/24 5:00:53 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Baxter International Inc.

    SC 13G - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    2/13/24 1:08:57 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Financials

    Live finance-specific insights

    View All

    Baxter Announces Increase in Maximum Tender Cap for 1.915% Senior Notes Due 2027

    Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced that it has increased the maximum purchase price for its $1.45 billion aggregate principal amount outstanding of 1.915% Senior Unsecured Notes due 2027 (the "2027 Notes") that it can repurchase under its previously announced cash tender offer for the 2027 Notes (the "2027 Notes Tender Offer") from $300 million to $600 million, on the terms and subject to the conditions set forth in the related Offer to Purchase dated Nov. 19, 2025 (the "Offer to Purchase"). The terms of the previously announced cash tender offer by Baxter for its 2.600% Senior Unsecured Notes due 2026 (the "2026 Notes Tender Offer" and, togethe

    11/19/25 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Declares Quarterly Dividend

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.01 per share of common stock. The dividend is payable on Jan. 2, 2026, to stockholders of record as of Nov. 28, 2025. The indicated annual dividend rate equates to $0.04 per share of common stock. "As we previously announced in conjunction with third-quarter 2025 earnings, we will be reducing the quarterly dividend beginning in January 2026," said Joel Grade, Baxter's executive vice president and chief financial officer. "This action is expected to free up more than $300 million in annual cash flow, consistent with our prior commitments an

    11/11/25 4:30:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Reports Third-Quarter 2025 Results

    Third-quarter sales from continuing operations of $2.84 billion increased 5% on a reported basis and 2% on an operational basis1,2 Third-quarter U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($0.10); adjusted diluted EPS from continuing operations of $0.69 Andrew Hider joined the company as president and chief executive officer (CEO), now leading the company's focus to drive continuous improvement and sustainable growth and create shareholder value Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2025. "I joined Baxter because it's a global healthcare leader – an iconic brand with an

    10/30/25 7:15:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care